End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.065 USD | -10.22% | -18.38% | +16.01% |
Mar. 25 | ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | CI |
Mar. 22 | ProKidney Posts Wider 2023 Loss | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 132M |
---|---|---|---|---|---|
Net income 2024 * | -157M | Net income 2025 * | -40M | EV / Sales 2024 * | - |
Net cash position 2024 * | 152M | Net cash position 2025 * | 295M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.61
x | P/E ratio 2025 * |
-2.65
x | Employees | 163 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.27% |
Latest transcript on ProKidney Corp.
1 day | -10.22% | ||
1 week | -18.38% | ||
1 month | +25.91% | ||
3 months | +57.63% | ||
6 months | +26.69% | ||
Current year | +16.01% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +1.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 2.065 | -10.22% | 630,119 |
24-04-29 | 2.3 | +8.49% | 778,763 |
24-04-26 | 2.12 | -21.77% | 1,533,641 |
24-04-25 | 2.71 | -.--% | 495,834 |
24-04-24 | 2.71 | +7.11% | 541,639 |
End-of-day quote Nasdaq, April 29, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.01% | 147M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- PROK Stock